NYSE:QGEN Qiagen - QGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Qiagen Please log in to your account or sign up in order to add this asset to your watchlist. $46.22 +0.28 (+0.61%) (As of 03/23/2023 01:03 PM ET) Add Compare Share Share Today's Range$45.89▼$46.4850-Day Range$45.29▼$50.6552-Week Range$40.38▼$51.18Volume147,450 shsAverage Volume666,995 shsMarket Capitalization$10.53 billionP/E Ratio25.12Dividend YieldN/APrice Target$55.53 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Qiagen MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside20.4% Upside$55.53 Price TargetShort InterestBearish2.29% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth8.53%From $2.11 to $2.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector558th out of 986 stocksBiological Products, Except Diagnostic Industry97th out of 165 stocks 2.1 Analyst's Opinion Consensus RatingQiagen has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.53, Qiagen has a forecasted upside of 20.4% from its current price of $46.13.Amount of Analyst CoverageQiagen has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.29% of the float of Qiagen has been sold short.Short Interest Ratio / Days to CoverQiagen has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Qiagen has recently increased by 12.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldQiagen does not currently pay a dividend.Dividend GrowthQiagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQiagen has received a 69.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pharmacovigilance services", "Clinical research services", and "Biochemical assay kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Qiagen is -0.83. Previous Next 1.3 News and Social Media Coverage News SentimentQiagen has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Qiagen this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for QGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Qiagen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Qiagen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Qiagen is held by insiders.Percentage Held by Institutions58.62% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Qiagen are expected to grow by 8.53% in the coming year, from $2.11 to $2.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Qiagen is 25.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Qiagen is 25.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.47.Price to Earnings Growth RatioQiagen has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQiagen has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Qiagen (NYSE:QGEN) StockQIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Read More Receive QGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter. Email Address QGEN Stock News HeadlinesMarch 13, 2023 | finance.yahoo.comQIAGEN Announces Form 20-F Annual Report Filing for 2022 ResultsMarch 10, 2023 | finance.yahoo.comQIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New PactMarch 23, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 9, 2023 | finance.yahoo.comQIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy DrugMarch 1, 2023 | finance.yahoo.comQIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation SequencingFebruary 28, 2023 | finance.yahoo.comInvesting in Qiagen (NYSE:QGEN) five years ago would have delivered you a 37% gainFebruary 14, 2023 | finance.yahoo.comQIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR frameworkFebruary 12, 2023 | finance.yahoo.comQiagen Full Year 2022 Earnings: EPS Misses ExpectationsMarch 23, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 7, 2023 | finance.yahoo.comQIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product GroupsFebruary 1, 2023 | finance.yahoo.comGenetic Technologies Shares Jump After Strategic Alliance With QiagenJanuary 31, 2023 | finance.yahoo.comQiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?January 24, 2023 | finance.yahoo.comQIAGEN's (QGEN) New Launch to Enhance Clinical Lab WorkflowJanuary 17, 2023 | finance.yahoo.comQIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic LabsJanuary 17, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)January 10, 2023 | finance.yahoo.comQIAGEN (QGEN) Acquires the Forensics NGS Firm VerogenJanuary 9, 2023 | finance.yahoo.comQIAGEN Acquires Verogen Strengthening Its Position In Human ID / ForensicsJanuary 9, 2023 | finance.yahoo.comQIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS TechnologiesJanuary 5, 2023 | finance.yahoo.comHelix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary DiseasesJanuary 5, 2023 | finance.yahoo.comQIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary DiseasesDecember 14, 2022 | finance.yahoo.comQIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA ApprovalDecember 13, 2022 | finance.yahoo.comQIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancerNovember 25, 2022 | finance.yahoo.comQIAGEN's (QGEN) New Monkeypox Test to Aid Faster IdentificationNovember 23, 2022 | finance.yahoo.com3 Reasons to Retain QIAGEN (QGEN) Stock in Your PortfolioNovember 21, 2022 | finance.yahoo.comQIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillanceNovember 19, 2022 | finance.yahoo.comIs Qiagen N.V.'s (NYSE:QGEN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?November 10, 2022 | finance.yahoo.comQIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View UpSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive QGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter. Email Address QGEN Company Calendar Last Earnings2/07/2023Today3/23/2023Next Earnings (Estimated)4/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:QGEN CUSIPN/A CIK1015820 Webwww.qiagen.com Phone(177) 355-6600Fax31-77-355-6658Employees6,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$55.53 High Stock Price Forecast$60.00 Low Stock Price Forecast$52.00 Forecasted Upside/Downside+20.4%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.84 Trailing P/E Ratio25.07 Forward P/E Ratio21.86 P/E Growth1.25Net Income$423.21 million Net Margins19.76% Pretax Margin23.94% Return on Equity16.45% Return on Assets8.71% Debt Debt-to-Equity Ratio0.42 Current Ratio2.46 Quick Ratio2.09 Sales & Book Value Annual Sales$2.14 billion Price / Sales4.91 Cash Flow$3.49 per share Price / Cash Flow13.21 Book Value$15.27 per share Price / Book3.02Miscellaneous Outstanding Shares227,716,000Free Float206,637,000Market Cap$10.50 billion OptionableOptionable Beta0.40 Key ExecutivesThierry BernardChief Executive Officer & Managing DirectorAntonio SantosSenior Vice President & Head-Global OperationsRoland SackersChief Financial Officer & Managing DirectorPhilipp von HugoVP, Head-Global Legal Affairs & ComplianceLezette YoungManager-Compliance & LegalKey CompetitorsRepligenNASDAQ:RGENBio-TechneNASDAQ:TECHNeurocrine BiosciencesNASDAQ:NBIXExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInstitutional OwnershipVoya Investment Management LLCBought 25,971 shares on 2/28/2023Ownership: 0.107%Macquarie Group Ltd.Bought 4,182 shares on 2/21/2023Ownership: 0.003%Alliancebernstein L.P.Sold 139,891 shares on 2/16/2023Ownership: 0.067%Eagle Asset Management Inc.Sold 325 shares on 2/15/2023Ownership: 0.013%Mariner LLCSold 517 shares on 2/15/2023Ownership: 0.006%View All Institutional Transactions QGEN Stock - Frequently Asked Questions Should I buy or sell Qiagen stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares. View QGEN analyst ratings or view top-rated stocks. What is Qiagen's stock price forecast for 2023? 5 brokers have issued 12-month target prices for Qiagen's stock. Their QGEN share price forecasts range from $52.00 to $60.00. On average, they anticipate the company's share price to reach $55.53 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts. How have QGEN shares performed in 2023? Qiagen's stock was trading at $49.87 at the start of the year. Since then, QGEN stock has decreased by 7.9% and is now trading at $45.94. View the best growth stocks for 2023 here. When is Qiagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. View our QGEN earnings forecast. How were Qiagen's earnings last quarter? Qiagen (NYSE:QGEN) posted its quarterly earnings data on Tuesday, February, 7th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.47 by $0.06. The business had revenue of $531 million for the quarter, compared to analyst estimates of $486.93 million. Qiagen had a net margin of 19.76% and a trailing twelve-month return on equity of 16.45%. Qiagen's revenue was down 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.74 EPS. What ETFs hold Qiagen's stock? ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), VanEck Biotech ETF (BBH), Newday Ocean Health ETF (AHOY), Franklin Genomic Advancements ETF (HELX) and WisdomTree BioRevolution Fund (WDNA). What guidance has Qiagen issued on next quarter's earnings? Qiagen issued an update on its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided earnings per share guidance of $2.10- for the period, compared to the consensus EPS estimate of $2.12. The company issued revenue guidance of $2.05B-, compared to the consensus revenue estimate of $2.07 billion. What is Thierry Bernard's approval rating as Qiagen's CEO? 33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees. What other stocks do shareholders of Qiagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX). What is Qiagen's stock symbol? Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN." Who are Qiagen's major shareholders? Qiagen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Amundi (3.27%), Norges Bank (2.53%), Pendal Group Ltd (1.89%), Arrowstreet Capital Limited Partnership (1.63%), Morgan Stanley (1.28%) and Marshall Wace LLP (0.97%). How do I buy shares of Qiagen? Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Qiagen's stock price today? One share of QGEN stock can currently be purchased for approximately $45.94. How much money does Qiagen make? Qiagen (NYSE:QGEN) has a market capitalization of $10.46 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.84 on an earnings per share basis. How many employees does Qiagen have? The company employs 6,000 workers across the globe. How can I contact Qiagen? Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658. This page (NYSE:QGEN) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.